Bottom line
Is BBP a good fund? The bottom line
BBP is an actively managed technology sector ETF from Virtus.
It charges 0.34% — about $34 a year on every $10,000 invested, cheaper than 94% of technology sector funds we track.
It returned +32.8% over one year, +8.4% a year over five years, +10.0% a year over ten (as of Dec 31, 2025, per its prospectus).
With $98.5 million in net assets and 70 holdings, its largest position is Crinetics Pharmaceuticals Inc (3.3%) and the top 10 make up 19.6% of the portfolio.
What stands out
- Low cost: cheaper than 94% of technology sector peers
Updated Nov 19, 2026
What BBP invests in
The Virtus Biotech ETF (formerly,Virtus LifeSci Biotech Products ETF) (the Fund ) seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index (the Underlying Index ).
Under normal market conditions, the Fund will invest not less than 80% of its assets in component securities of the Underlying Index. The Underlying Index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ( FDA ) for marketing. The Underlying Index is sponsored by LifeSci Index Partners, LLC (the Index Provider ). The Index Provider utilizes a selection committee comprised of its employees (the Index Committee ) that is responsible, pursuant to the rules included in the methodology for the Underlying Index, for making certain determinations for the Underlying Index, as more fully described below. The Index Committee utilizes various public data sources to make determinations, including, but not limited to, Securities and Exchange Commission ( SEC ) filings…
From the fund's prospectus (filed Feb 27, 2026).
BBP performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| BBP | +32.8% | +8.4% | +10.0% |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Dec 31, 2025
What BBP costs
On a $10,000 investment, BBP's 0.34% expense ratio costs about $34 a year. The prospectus estimates $431 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
BBP top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Crinetics Pharmaceuticals Inc CRNX | 3.34% |
| 2 | Kiniksa Pharmaceuticals International Plc KNSA | 1.97% |
| 3 | Verastem Inc VSTM | 1.95% |
| 4 | Precigen Inc PGEN | 1.94% |
| 5 | Omeros Corp OMER | 1.87% |
| 6 | Nuvation Bio Inc NUVB | 1.77% |
| 7 | Regeneron Pharmaceuticals REGN | 1.72% |
| 8 | Protagonist Therapeutics Inc PTGX | 1.71% |
| 9 | Acadia Pharmaceuticals Inc ACAD | 1.69% |
| 10 | Bridgebio Pharma Inc BBIO | 1.65% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 19.6% of the fund. See all top 25 holdings and asset mix →